Loring Wolcott & Coolidge Fiduciary Advisors LLP Abb Vie Inc. Transaction History

Loring Wolcott & Coolidge Fiduciary Advisors LLP

$11.1 Billion
Q3 2024

A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Abb Vie Inc. stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 60,076 shares of ABBV stock, worth $10.3 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

60,076

Previous 60,013 0.1%

Holding current value

$10.3 Million

Previous $10.3 Million 15.25%

% of portfolio

0.11%

Previous 0.1%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 25, 2024	BUY	$163.84 - $199.33 $10,321 - $12,557	63 Added 0.1%	60,076 $11.9 Million
Q2 2024 Jul 17, 2024	BUY	$154.79 - $180.76 $254,319 - $296,988	1,643 Added 2.81%	60,013 $10.3 Million
Q1 2024 Apr 23, 2024	SELL	$159.82 - $182.1 $137,125 - $156,241	-858 Reduced 1.45%	58,370 $10.6 Million
Q4 2023 Feb 01, 2024	SELL	$137.6 - $154.97 $277,401 - $312,419	-2,016 Reduced 3.29%	59,228 $9.18 Million
Q3 2023 Nov 03, 2023	SELL	$133.59 - $154.65 $543,043 - $628,652	-4,065 Reduced 6.22%	61,244 $9.13 Million
Q2 2023 Aug 01, 2023	SELL	$132.51 - $164.9 $44,788 - $55,736	-338 Reduced 0.51%	65,309 $8.8 Million
Q1 2023 May 02, 2023	SELL	$144.61 - $166.54 $239,763 - $276,123	-1,658 Reduced 2.46%	65,647 $10.5 Million
Q4 2022 Mar 02, 2023	BUY	$138.31 - $165.87 $6,915 - $8,293	50 Added 0.07%	67,305 $10.9 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $31,811 - $38,150	230 Added 0.34%	67,255 $9.99 Million
Q3 2022 Oct 25, 2022	SELL	$134.21 - $153.93 $41,068 - $47,102	-306 Reduced 0.45%	67,025 $9 Million
Q2 2022 Jul 26, 2022	BUY	$137.62 - $174.96 $103,490 - $131,569	752 Added 1.13%	67,331 $10.3 Million
Q1 2022 Apr 13, 2022	SELL	$131.98 - $163.75 $430,650 - $534,316	-3,263 Reduced 4.67%	66,579 $10.8 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $668,107 - $845,348	-6,219 Reduced 8.18%	69,842 $9.46 Million
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $58,520 - $66,429	550 Added 0.73%	76,061 $8.21 Million
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $145,505 - $162,101	1,383 Added 1.87%	75,511 $8.51 Million
Q1 2021 Apr 14, 2021	SELL	$102.3 - $112.62 $618,403 - $680,787	-6,045 Reduced 7.54%	74,128 $8.02 Million
Q4 2020 Jan 14, 2021	SELL	$80.49 - $108.67 $20,927 - $28,254	-260 Reduced 0.32%	80,173 $8.59 Million
Q3 2020 Oct 15, 2020	SELL	$85.91 - $100.83 $281,870 - $330,823	-3,281 Reduced 3.92%	80,433 $7.05 Million
Q2 2020 Jul 30, 2020	SELL	$73.37 - $98.18 $86,209 - $115,361	-1,175 Reduced 1.38%	83,714 $8.22 Million
Q1 2020 Apr 15, 2020	SELL	$64.5 - $97.79 $238,327 - $361,334	-3,695 Reduced 4.17%	84,889 $6.47 Million
Q4 2019 Jan 22, 2020	SELL	$72.13 - $90.25 $346,296 - $433,290	-4,801 Reduced 5.14%	88,584 $7.84 Million
Q3 2019 Nov 05, 2019	BUY	$62.98 - $75.72 $92,832 - $111,611	1,474 Added 1.6%	93,385 $7.07 Million
Q2 2019 Aug 09, 2019	SELL	$65.7 - $83.98 $169,046 - $216,080	-2,573 Reduced 2.72%	91,911 $6.68 Million
Q1 2019 Apr 08, 2019	SELL	$77.14 - $90.79 $497,861 - $585,958	-6,454 Reduced 6.39%	94,484 $7.61 Million
Q4 2018 Feb 13, 2019	BUY	$77.85 - $96.01 $101,905 - $125,677	1,309 Added 1.31%	100,938 $9.31 Million
Q3 2018 Oct 31, 2018	SELL	$88.91 - $98.84 $519,856 - $577,917	-5,847 Reduced 5.54%	99,629 $9.42 Million
Q2 2018 Aug 07, 2018	SELL	$89.78 - $106.23 $488,582 - $578,103	-5,442 Reduced 4.91%	105,476 $9.77 Million
Q1 2018 Apr 20, 2018	SELL	$92.01 - $123.21 $28,155 - $37,702	-306 Reduced 0.28%	110,918 $10.5 Million
Q4 2017 Feb 08, 2018	SELL	$89.56 - $98.21 $28,569 - $31,328	-319 Reduced 0.29%	111,224 $10.8 Million
Q3 2017 Oct 27, 2017	SELL	$69.85 - $89.22 $121,399 - $155,064	-1,738 Reduced 1.53%	111,543 $9.91 Million
Q2 2017 Aug 07, 2017	BUY	N/A	113,281	113,281 $0

Others Institutions Holding ABBV

# of Institutions

3,846

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $304B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.

Account

Loring Wolcott & Coolidge Fiduciary Advisors LLP Abb Vie Inc. Transaction History